Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...
Publications
2 shownPan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Mining immunotherapy clinical trials Clinical trial data can provide a wealth of information about how drugs work. Yet such information often belongs to pharmaceutical companies...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 4,918
- Institution
- Dana-Farber Cancer Institute
External Links
Identifiers
- ORCID
- 0000-0002-4253-943X
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.